A Study of TG103 Injection in Overweight/Obese Subjects Without Diabetes

Summary

The main purpose of this study is to assess the safety and tolerability of multiple doses of TG103 injection in overweight/obese subjects without diabetes

Timeline

Start

2021-07-01

Primary completion

2022-12-01

Completion

2023-01-01

Publications

• Lin D, Xiao H, Yang K, Li J, Ye S, Liu Y, Jing S, Lin Y, Yang Y, Huang L, Yuan J, Li Z, Yang J, Gao H, Xie Y, Xu M, Yan L. Safety, tolerability, pharmacokinetics, and pharmacodynamics of TG103 injection in participants who are overweight or obese: a randomized, double-blind, placebo-controlled, multiple-dose phase 1b study. BMC Med. 2024 May 29;22(1):209. doi: 10.1186/s12916-024-03394-z.

Drugs

Indications